Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Lenvatinib (off Label)

Lenvatinib MSK Phase 2

Eisai (investigator studies) · Phase 2 · Active, not recruiting · Enrollment 33

NCT02780310

Catalyst Primary completion. 05.2027. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmPopulationDoseEstimandComparatorEfficacy
Lenvatinib 24 mgprogressive R/M ACC (n = 32 evaluable)24 mgSingle armn/robjective response rate: 15.6%, primary analysismedian progression-free survival: 17.5 months, 8 progression events